Novo Nordisk’s Bold Gambit: Price Cuts and Restructuring Amid Market Pressure

Facing intense competitive pressure, Danish pharmaceutical giant Novo Nordisk is implementing a radical strategic shift. The company has announced dramatic price reductions for its blockbuster drugs Wegovy and Ozempic, coupled with a significant corporate restructuring that will eliminate approximately 9,000 positions globally. This aggressive move comes as Novo Nordisk’s shares have plummeted more than 50% since the beginning of the year.

Competitive Landscape Shifts Dramatically

The market dynamics for GLP-1 medications have transformed considerably, with competitor Eli Lilly gaining substantial ground through its offerings Zepbound and Mounjaro. Market share data reveals the severity of Novo Nordisk’s position: the company’s international GLP-1 business share has collapsed from 71.6% to just 56.3% within a single year.

In response, Novo Nordisk is launching a pricing offensive, slashing the monthly cost of Wegovy and Ozempic to $349 for self-paying patients. This substantial reduction aims to capture millions of underinsured or uninsured patients, leveraging production scale to pressure competitors. The strategy appears clear: establish an aggressive pricing floor that challenges rivals to match.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Corporate Restructuring and Financial Implications

The strategic pivot carries significant financial consequences. To fund this new growth initiative and compensate for shrinking margins, Novo Nordisk has unveiled a comprehensive restructuring plan:

• Global workforce reduction of approximately 9,000 employees
• One-time restructuring costs totaling 9 billion Danish kroner
• Projected annual savings of about 8 billion kroner by end of 2026
• Revised 2025 revenue growth forecast lowered to 8-11%

Wall Street has responded with skepticism to these developments. Concerns about compressed profit margins and slowing growth have driven the stock downward from its 52-week high of over €106 to approximately €42 per share—representing a 60% decline.

Strategic Crossroads for Weight Loss Market Leader

Novo Nordisk appears to be betting everything on a volume-over-margin approach, prioritizing mass market penetration over premium pricing. The critical question remains whether this strategic reversal can reclaim the company’s former dominance in the rapidly expanding obesity medication market, or whether it will trigger a destructive price war with no clear winners.